PepGen (PEPG) Operating Leases (2022 - 2026)
PepGen (PEPG) posted Operating Leases of $13.4 million for Q1 2026, down 3.37% sequentially from $13.8 million in Q4 2025, and down 11.92% YoY from $15.2 million in Q1 2025.
Analysis
PepGen (PEPG) Operating Leases (2022 - 2026) Analysis & Trends
PepGen has reported Operating Leases for 5 years, with the latest figure at $13.4 million in Q1 2026.
- Quarterly Operating Leases fell 11.92% year-over-year to $13.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.4 million (down 11.92% YoY) and the FY2025 annual result came in at $13.8 million, down 11.24% from the prior year.
- Operating Leases retreated to $13.4 million in Q1 2026 per PEPG's latest filing, from $13.8 million in the prior quarter.
- Over five years, Operating Leases peaked at $19.0 million in Q4 2022 and troughed at $13.4 million in Q1 2026.
- A 5-year average of $16.1 million and a median of $16.2 million in 2024 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2024 and 2026: Operating Leases slipped 7.86% in 2024, then decreased 11.92% in 2026.
- Over 5 years, Operating Leases stood at $19.0 million in 2022, then dropped by 9.91% to $17.1 million in 2023, then slipped by 8.96% to $15.6 million in 2024, then dropped by 11.24% to $13.8 million in 2025, then decreased by 3.37% to $13.4 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $13.4 million, $13.8 million, and $14.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | PepGen | 217.99 Mn | 217.99 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.86 Mn |
| Mar 31, 2026 | 13.35 Mn |
| Dec 31, 2025 | 13.82 Mn |
| Sep 30, 2025 | 14.28 Mn |
| Jun 30, 2025 | 14.72 Mn |
| Mar 31, 2025 | 15.16 Mn |
| Dec 31, 2024 | 15.57 Mn |
| Sep 30, 2024 | 15.97 Mn |
| Jun 30, 2024 | 16.36 Mn |
| Mar 31, 2024 | 16.74 Mn |
| Dec 31, 2023 | 17.10 Mn |
| Sep 30, 2023 | 17.45 Mn |
| Jun 30, 2023 | 17.87 Mn |
| Mar 31, 2023 | 18.17 Mn |
| Dec 31, 2022 | 18.98 Mn |